Introduction
============

Cisplatin (*Cis*-diamminedichloroplatinum) is a potent chemotherapeutic drug (Figure [1A](#F1){ref-type="fig"}), used in the management of several malignancies, such as advanced bladder carcinoma and metastatic ovarian and testicular tumors ([@B13]). However, its clinical use is restricted due to tumor resistance and major dose-related side effects, such as nephrotoxicity, ototoxicity, and bone marrow depression ([@B2]; [@B41]; [@B9]). With the early clinical application of cisplatin, more than 50% of patients reported dose-related renal insufficiency ([@B15]); however, using saline hydration and diuresis during cisplatin administration reduced these rates to about 20% ([@B17]). Among the several mechanisms that were proposed for cisplatin-induced renal damage, the oxidative stress-mediated cytotoxicity has been prominent. Cisplatin induces mitochondrial dysfunction through inhibition of the mitochondrial complexes (I--IV), increasing the production of reactive oxygen species (ROS) ([@B24]). Moreover, cisplatin directly interacts with glutathione (GSH), suppressing its antioxidant effect ([@B2]; [@B43]).

![The chemical structure of **(A)** cisplatin, **(B)** resveratrol, and **(C)** benzyl isothiocyanate.](fphar-09-01268-g001){#F1}

Resveratrol is a polyphenolic phytoalexin (present naturally in grapes and berries) (Figure [1B](#F1){ref-type="fig"}) that possesses antioxidant, anti-infective, and cardioprotective effects ([@B12]; [@B5]). Previous studies have revealed the renoprotective effects of RES against diabetic nephropathy ([@B42]; [@B36]), renal injuries induced by aldosterone ([@B50]), ischemia--reperfusion and sepsis ([@B14]; [@B18]), as well as drug-related nephrotoxicity ([@B28]). Resveratrol (RES) exerts its cytoprotective effect by scavenging ROS, including the hydroxyl, superoxide, and peroxynitrite radicals ([@B27]; [@B19]). Moreover, it modulates the expression and activities of endogenous antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) ([@B30]; [@B40]; [@B23]).

Benzyl isothiocyanate (BITC) is a natural compound (Figure [1C](#F1){ref-type="fig"}), present in cruciferous vegetables ([@B29]). In a study to investigate the chemopreventive effects of ITCs, BITC significantly ameliorated the oxidative burst by inhibiting the leukocytic NADPH oxidase, which produces large amounts of superoxide radicals ([@B29]). Moreover, BITC has a chemosensitizing activity, which improves the efficacy of cisplatin chemotherapy ([@B48]; [@B31]). This is probably because it induces apoptosis in tumor cells through the activation of mitogen-activated protein kinases (MAPKs) and inhibition of the extracellular signal-regulated kinase ([@B26]).

To our knowledge, there is a lack of published data over the chemoprotective effect of BITC against cisplatin-induced nephrotoxicity. Therefore, the aims of this experiment were to investigate the renoprotective effects of BITC, to compare its efficacy to the established antioxidant (RES), and to assess the efficacy of BITC--RES combination against cisplatin-induced nephrotoxicity in mice.

Materials and Methods {#s1}
=====================

Chemicals
---------

Cisplatin (1 mg/ml vial) in a clinical formulation and BITC were obtained from Sigma (St. Louis, MO, United States), while RES was bought from NOW Foods (IL, United States). All biochemical analysis kits were purchased from Biodiagnostics Company (Dokki, Giza, Egypt) except tumor necrosis factor-α (TNF-α) (BioSource International, Camarillo, CA, United States) and interleukin-1β (IL-1β) kits (Glory Science Ltd., Del Rio, TX, United States). All other chemicals were of high analytical grades.

Animals and Experimental Design
-------------------------------

Forty Swiss Albino mice (males, weight 22 ± 5 g) were obtained from the Egyptian Company for Biological Products and Vaccines. Animals were acclimatized in a well-ventilated room with normal light/dark (12 h each) cycle and temperature (25 ± 2°C) and were supplied with adequate food and water. The animal handling procedures in this study were approved by the local Research Ethical Committee at Suez Canal University, Egypt (Approval No.: 201513).

Mice were randomly allocated into five groups (*n* = 8 per group). Group I mice received normal saline and acted as a negative control group. Mice in the other four groups received a single intraperitoneal (i.p.) dose of cisplatin (20 mg/kg) at the sixth day of the experiment ([@B46]). Moreover, mice in group III \[cisplatin (CDDP)--BITC\] received daily oral supplementation with BITC (100 mg/kg in diet) for 10 days ([@B22]) and mice in group IV (CDDP--RES) received daily oral supplementation with RES (30 mg/kg) for the same duration ([@B51]). Mice in group V (CDDP--BITC--RES) received a combination of BITC and RES for 10 days (at the same aforementioned doses) (Figure [2](#F2){ref-type="fig"}).

![A flow diagram of animal allocation, treatment regimens, and outcome assessment. BITC: benzyl isothiocyanate, CAT: catalase, GPx: glutathione peroxidase, GSH: glutathione, IL-1β: interleukin-1β, MDA: malondialdehyde, RES: resveratrol, SOD: superoxide dismutase, and TNF: tumor necrosis factor.](fphar-09-01268-g002){#F2}

Biochemical Analysis
--------------------

On the 11th day, blood samples were obtained under isoflurane anesthesia. After clotting at 25°C, samples were centrifuged for 15 min (at 3000 rpm) and the resulting sera were stored at −20°C until used to assess the serum concentrations of creatinine and urea, according to the methods by [@B25] and [@B8], respectively.

Later, mice were sacrificed and tissue pieces of the mice kidneys were removed, washed with saline, and homogenized in potassium phosphate buffer. Then, the homogenate underwent two cycles of centrifugation (at 600 and 10,000 × *g*) and supernatants were utilized to measure the concentrations of MDA \[lipid peroxidation marker according to Uchiyama and Mihara ([@B45])\], GSH (according to [@B4]), GPx (according to [@B35]), SOD (according to [@B33]), and CAT (according to [@B1]). The serum and tissue concentrations of IL-1β and TNF-α were measured as per the manufacturer's instructions and the absorbance was read by an automated ELISA reader at 420 nm.

Histopathology and Immunohistochemistry
---------------------------------------

Parts of the removed mice kidneys were fixed in 10% buffered formalin and were then embedded into paraffin blocks. Then, 4-μm-thick sections were cut and stained with hematoxylin and eosin (H&E) and examined with a light microscope. Histopathological alterations were evaluated using a semiqunatitative scale. Renal sections were examined blindly (10 fields per slide) at 400× magnification. The used scoring system was (0: normal, 1: \<10%, 2: 11--25%, 3: 26--45%, 4: 46--75%, 5: \>76%) for the percentage of epithelial cell necrosis, tubular cast, degree of interstitial inflammation, and tubular dilation.

For immunohistochemical examination, paraffin-embedded renal sections were de-paraffinized (in xylene) and rehydrated in alcohol, followed by antigen unmasking in citrate buffer (pH 6.0); 5% normal goat or rabbit serum in phosphate-buffered saline was used to block non-specific binding sites. Later, sections were incubated with primary antibodies against Cox-II (1:100), followed by specific biotin-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA, United States). For color development, Vector-ABC streptavidin-peroxidase kits were added to the slides and sections were counterstained with diluted hematoxylin. For quantification, positively stained cells (brown-colored) were identified using the double color thresholding of ImageJ program.

Data Analysis
-------------

All obtained values were expressed as means ± standard deviations (SD), calculated by SPSS (version 22, Chicago, IL, United States). The significance of between-group differences was tested using the one-way Analysis of Variance, followed by the *post hoc* Tukey's test. The results of all groups were evaluated in comparison to the control and CDDP groups. Moreover, the results of the CDDP--BITC group were compared to those of the CDDP--RES and CDDP--BITC--RES groups. The significance of these differences was assigned at a *p*-value of \<0.05.

Results
=======

Biochemical Serum Analysis
--------------------------

Compared to normal control mice, cisplatin-intoxicated mice showed significantly (*p* \< 0.05) higher serum levels of urea, creatinine (Figure [3](#F3){ref-type="fig"}), TNF-α and IL-1β (Figures [4A,C](#F4){ref-type="fig"}). However, cisplatin-intoxicated mice, treated by RES and BITC, alone or in combination, had significantly lower (*p* \< 0.05) serum levels of the aforementioned parameters than those treated with cisplatin alone. The effects of both compounds were comparable in all assessed parameters, except IL-1β serum concentration (that was significantly lower in the RES-treated group). Interestingly, the serum concentrations of these parameters were restored to the normal ranges in the combination treatment group.

![The effects of RES and BITC treatment on serum concentrations of **(A)** urea and **(B)** creatinine in cisplatin-intoxicated mice. Data are means ± standard deviations. CDDP, cisplatin. ^∗^Significantly different from the normal control group at *p* \< 0.05. ^\#^Significantly different from the CDDP group at *p* \< 0.05.](fphar-09-01268-g003){#F3}

![The effects of RES and BITC treatment on serum and renal tissue levels of **(A,B)** tumor necrosis factor-α **(C,D)** interleukin-1β in cisplatin-intoxicated mice. Data are means ± standard deviations. CDDP, cisplatin. ^∗^Significantly different from the normal control group at *p* \< 0.05. ^\#^Significantly different from the CDDP group at *p* \< 0.05. Additionally, note that serum IL-1β concentration in CDDP--RES group is significantly lower than in the CDDP--BITC group (*p* \< 0.05).](fphar-09-01268-g004){#F4}

Biochemical Tissue Analysis
---------------------------

Cisplatin-intoxicated mice exhibited significantly higher levels of MDA, TNF-α and IL-1β (Figures [4B,D](#F4){ref-type="fig"}), as well as significantly lower (*p* \< 0.05) GSH concentration and enzymatic activities of GPx, SOD, and CAT in comparison to normal controls. On the other hand, cisplatin-intoxicated mice co-treated with RES or BITC or a combination of both showed significantly lower MDA, IL-1β, and TNF-α levels and significantly higher (*p* \< 0.05) GSH concentration and antioxidant enzymatic activities. The effects of both compounds were comparable in all assessed parameters, except renal tissue MDA concentration (that was significantly lower in the RES-treated group). Of note, treatment with RES or RES plus BITC restored the normal tissue concentrations of some (GPx and CAT) or all aforementioned parameters, respectively (Table [1](#T1){ref-type="table"}).

###### 

The effects of RES and BITC treatment on renal tissue lipid peroxidation GSH concentration and activities of antioxidantenzymes in cisplatin-intoxicated mice.

                 Control        CDDP             CDDP--BITC         CDDP--RES           CDDP--RES--BITC
  -------------- -------------- ---------------- ------------------ ------------------- -----------------
  MDA (nmol/g)   5.1 ± 0.78     14.9 ± 1.4^∗^    10.9 ± 1.45^∗\#^   8.9 ± 1.22^∗\#^     5.8 ± 1.04^\#^
  GSH (mmol/g)   13.6 ± 0.77    5.2 ± 0.75^∗^    10.7 ± 0.61^∗\#^   11.24 ± 1.14^∗\#^   13.4 ± 2.1^\#^
  GPx (mol/g)    6.92 ± 1.4     2.98 ± 0.63^∗^   4.9 ± 1.04^∗\#^    5.6 ± 0.94^\#^      6.6 ± 0.97^\#^
  SOD (U/g)      20.75 ± 4.14   7.2 ± 1.6^∗^     11.7 ± 1.9^∗\#^    14.5 ± 2.1^∗\#^     19.8 ± 2.6^\#^
  CAT (U/g)      4.35 ± 0.52    1.9 ± 0.55^∗^    3.03 ± 0.32^∗\#^   3.54 ± 0.75^\#^     4.17 ± 0.87^\#^

Data are means ± standard deviations. CDDP, cisplatin; GSH, glutathione.

∗

Significantly different from the normal control group at p \< 0.05.

\#

Significantly different from the CDDP group at p \< 0.05. Note that the all parameters are comparable in CDDP--RES and CDDP--BITC groups, except for MDA, which is significantly lower in the CDDP--RES group (p \< 0.05).

Histopathological Examination
-----------------------------

Control mice showed normal renal histology (Figure [5A](#F5){ref-type="fig"}), whereas those injected with cisplatin exhibited pathological alterations in about 40% of renal tubules, especially in the renal cortex and the corticomedullary junction. Affected tubules were ecstatic and tortuous. Their lining epithelium was attenuated or contained clear vacuoles within the cytoplasm. Some epithelial cells had hypereosinophilic cytoplasm with pyknotic nuclei (necrosis). The lumina of some tubules were filled with homogenous eosinophilic materials. Moreover, the interstitial tissue showed multifocal infiltration with moderate numbers of lymphocytes and macrophages (Figure [5B](#F5){ref-type="fig"}).

![H&E sections of the kidney (Bar = 50 μm). **(A)** Saline-treated mice revealing normal kidney tissue morphology. **(B)** Cisplatin-treated mice revealing marked dilation and twisting of several renal tubules (arrows). **(C)** Slight improvement of renal tissue in CDDP--RES-treated mice (arrows). **(D)** Moderate histopathologic changes are seen in CDDP--BITC-treated mice (arrow). **(E)** Mice treated with BITC and RES combination showing mild morphologic changes. **(F)** Semiquantitative analysis of the histopathological changes (^∗^significantly different from the normal control group at *p* \< 0.05, ^\#^significantly different from the CDDP group at *p* \< 0.05).](fphar-09-01268-g005){#F5}

On the contrary, mice treated with RES (Figure [5C](#F5){ref-type="fig"}) or BITC (Figure [5D](#F5){ref-type="fig"}) alone showed moderate comparable degrees of the previously mentioned histopathological changes in about 25--30% of renal tubules. Interestingly, the renal tissue from mice that received both RES and BITC showed minimal pathological alterations in few scattered tubules (Figure [5E](#F5){ref-type="fig"}). Semiquantitative analysis showed that treatment with BITC or RES alone significantly reduced the renal tissue histopathological changes, compared to mice treated with cisplatin alone. This reduction was more significant in the BITC--RES combination group than in mice, treated with RES or BITC alone (Figure [5F](#F5){ref-type="fig"}).

Immunohistochemical Examination
-------------------------------

Cisplatin exposure in mice significantly increased the protein expression of COX-II enzyme within the cytoplasm of the tubular epithelial cells (Figure [6B](#F6){ref-type="fig"}) in comparison to the control group which revealed mild or absent immunoreactivity (Figure [6A](#F6){ref-type="fig"}). Cisplatin-intoxicated mice that received either RES (Figure [6C](#F6){ref-type="fig"}) or BITC (Figure [6D](#F6){ref-type="fig"}) showed comparable significant reductions in the expression of COX-II enzyme in comparison to mice treated with cisplatin alone. The Cox-II expression was significantly lower in the combination group (Figure [6E](#F6){ref-type="fig"}) than in mice, treated with RES or BITC alone (Figure [6F](#F6){ref-type="fig"}).

![COX-II immunohistochemical examination (Bar = 50 μm) of renal tissue samples from **(A)** saline-treated mice showing minimal COX-II expression, **(B)** cisplatin-intoxicated mice revealing many Cox-II-positive epithelial cells (arrows), **(C)** cisplatin-intoxicated mice treated with RES and **(D)** cisplatin-intoxicated mice treated with BITC showing moderate reductions in COX-II-positive cells (arrow), and **(E)** cisplatin-intoxicated mice treated with a combination of RES and BITC showing minimal COX-II expression. **(F)** Quantitative Cox-II expression in the cytoplasm of renal epithelial cells (^∗^significantly different from the normal control group at *p* \< 0.05, ^\#^significantly different from the CDDP group at *p* \< 0.05).](fphar-09-01268-g006){#F6}

Discussion
==========

To our knowledge, this experiment is the first to examine the nephroprotective effects of BITC and RES combination against cisplatin-induced nephrotoxicity. The main findings in this study were that RES and BITC could improve the cisplatin-induced: (1) acute kidney injury (histological improvement and reduction of serum urea and creatinine levels), (2) inflammation (reduction of IL-1β and TNF-α levels in the serum and kidney, reduced COX-II expression in the renal tissue, and reduced leukocytic infiltration on histopathological examination), and (3) oxidative stress (reduced renal tissue MDA and NO levels and increased GSH concentration and enzymatic activities of SOD and CAT). Moreover, the nephroprotective effects in all investigated parameters were more significant with the BITC--RES combination than with either drug alone.

The mechanisms of cisplatin-induced nephrotoxicity are sophisticated; however, the induction of oxidative stress and inflammation remains the most established theory. In agreement with previous studies, cisplatin administration in laboratory animals induced oxidative stress and suppressed the endogenous antioxidant machinery ([@B28]; [@B44]). Moreover, we showed that cisplatin increases serum and tissue levels of TNF-α, which can be produced by several immune and non-immune cells, including the renal epithelium. TNF-α can induce direct toxicity to glomerular and tubular cells and activate the intrinsic and extrinsic apoptotic pathways ([@B37], [@B38], [@B39]). In the same vein, the increased serum and tissue levels of IL-1β and the upregulated expression of COX-II increase the production of prostaglandin-E2 by renal mesangial cells, which changes the glomerular hemodynamics and filtration ([@B11]) (as reflected on serum urea and creatinine in our data).

To minimize the nephrotoxic effects of cisplatin, we investigated whether BITC and RES, which are natural food-based compounds, can protect the renal tissues against cisplatin-induced nephrotoxicity. Our data revealed that RES mitigated cisplatin-induced oxidative stress and inflammation, confirming the findings of previous studies in that regard ([@B10]; [@B47]; [@B34]). Although RES is established as an antioxidant, [@B24] suggested that cisplatin cytotoxicity is not directly related to lipid peroxidation and that it induces ROS production due to leukocytic infiltration. Therefore, the anti-inflammatory effect of RES may be more important than its antioxidant role in this regard. Another study by [@B22] attributed the nephroprotective effect of RES against cisplatin toxicity to increasing SIRT1 enzyme expression, which inhibits cisplatin-induced p53 apoptosis ([@B21]).

Likewise, our study showed that BITC exerted an antioxidant activity by ameliorating cisplatin-induced inflammation and upregulating the expression of antioxidant enzymes. Other studies showed that BITC can suppress inflammation-related carcinogenesis by suppressing superoxide radicals' generation within inflammatory leukocytes, exposed to the pro-oxidant \[12-*O*-tetradecanoylphorbol-13-acetate (TPA)\] ([@B29]; [@B32]). In addition, both agents (RES and BITC) have shown a chemosensitizing effect with cisplatin by increasing tumor cell uptake of cisplatin ([@B34]) or initiating apoptosis in tumor cells ([@B48]; [@B31]). Therefore, their combination with cisplatin can offer extra protection and a more potent antimutagenic efficacy.

Comparing both agents (BITC and RES) showed that BITC exerted comparable nephroprotective, antioxidant, and anti-inflammatory effects to RES in most assessed parameters. However, the reductions in the serum IL-1β and renal tissue MDA concentrations were more significant in the RES-treated group, compared to the BITC-treated group. Moreover, RES could restore the normal renal tissue concentrations of GPx and CAT enzymes. Whether these few differences are due to additional molecular mechanisms for RES or could be negated by increasing BITC dose should be further investigated. Overall, the nephroprotective effects of both compounds were comparable.

Interestingly, the combination of RES and BITC showed significantly more potent antioxidant and anti-inflammatory activities than either agent alone. These findings indicate that BITC augments the antioxidant and anti-inflammatory effects of RES by increasing the expression of antioxidant enzymes and reducing the expression of pro-inflammatory cytokines. Further studies should investigate if other mechanisms are involved in BITC--RES combination nephroprotection. A limitation of this study is that the drug combination index (DCI) was not calculated to determine whether the effects of both agents are additive or synergistic ([@B6]; [@B7]). Future studies are encouraged to determine this relationship and test the drug combination in animal models with malignant tumors, receiving cisplatin chemotherapy.

Histopathological and immunohistochemical examinations confirmed the findings of our biochemical analysis. The observed cellular degeneration and tubular casts indicate impaired glomerular filtration and account for the recorded deteriorations in renal functions. Similarly, the increased leukocytic infiltration goes in parallel with the increased serum and tissue levels of TNF-α and IL-1β. Similar observations were recorded in former studies on cisplatin nephrotoxicity ([@B10]; [@B44]). In contrast, concomitant treatment with BITC or RES significantly ameliorated all pathological changes and these effects were more marked in the combination group than in either agent groups. In agreement with previous studies, cisplatin-induced renal injury is associated with increased COX-II expression ([@B20]; [@B49]). Besides synthesizing pro-inflammatory cytokines, COX-II is involved in the production of vasoconstrictor thromboxanes, leading to reduced renal blood flow and impaired renal function ([@B3]; [@B16]). Further, our results confirm the results of former investigations that amelioration of cisplatin nephrotoxicity involves the inhibition of COX-II expression ([@B20]; [@B49]). This enhances the potential of COX-II enzyme as a therapeutic target for cisplatin-induced nephrotoxicity.

Conclusion
==========

Benzyl isothiocyanate exerted nearly comparable nephroprotective, antioxidant, and anti-inflammatory effects to RES. Moreover, the combination of both agents showed more potent protective effects than any agent alone. Further experimental and clinical investigations are required to confirm these findings and investigate their future therapeutic applications.
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